Investment Thesis
Artiva Biotherapeutics is a pre-revenue clinical-stage biopharmaceutical company burning significant cash with no approved products or revenue generation. The company is consuming approximately $80M annually in free cash flow with only $26.7M in cash reserves, indicating a critical runway issue within 4-6 months without additional financing.
Strengths
- Strong balance sheet with minimal debt ($0M long-term debt) and debt-free capital structure
- Adequate liquidity position currently with 8.61x current ratio despite cash burn
- Recent insider activity with 7 Form 4 filings suggesting active leadership engagement
Risks
- Zero revenue with 100% YoY revenue decline - no commercial progress or approved products
- Severe cash burn of $76.8M in operating cash flow and $79.3M negative free cash flow annually
- Critical cash runway crisis - only $26.7M cash reserves against $79.3M annual burn rate creates existential dilution risk within months
- Massive shareholder value destruction with -76.3% ROE and -64.0% ROA
- Operating losses of $89.8M indicate no clear path to profitability or commercialization success
Key Metrics to Watch
- Cash balance and runway to next milestone/financing event
- Clinical trial progress and regulatory pathway milestones
- Monthly cash burn rate and operating cash flow trends
- Capital raise announcements and dilution per share
- Operating expense reduction initiatives
Financial Metrics
Revenue
0.0
Net Income
-83.9M
EPS (Diluted)
$-3.43
Free Cash Flow
-79.3M
Total Assets
130.9M
Cash
26.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-76.3%
ROA
-64.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
8.61x
Quick Ratio
8.61x
Debt/Equity
0.00x
Debt/Assets
16.0%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T04:42:11.129831 |
Data as of: 2025-12-31 |
Powered by Claude AI